HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sodium cromoglycate and eformoterol attenuate sensitivity and reactivity to inhaled mannitol in subjects with bronchiectasis.

AbstractBACKGROUND AND OBJECTIVE:
Dry powder mannitol has the potential to be used to enhance clearance of mucus in subjects with bronchiectasis. A reduction in FEV1 has been recorded in some subjects with bronchiectasis after inhaling mannitol. The aim of this study was to investigate if pre-medicating with either sodium cromoglycate (SCG) or eformoterol could inhibit this reduction in FEV1.
METHODS:
A double-blind, placebo-controlled, randomized cross-over study was conducted. Lung function and airway response to mannitol was assessed on a control day and then re-assessed after pre-medication with placebo, SCG and eformoterol in nine subjects. Sensitivity to mannitol, expressed as the dose required to induce a 15% fall in FEV1 (PD15), and reactivity to mannitol, expressed as the % fall in FEV1 per mg of mannitol (response-dose ratio, RDR), are reported.
RESULTS:
Subjects had an FEV1 of 68 ± 14% predicted, FVC of 97 ± 15% predicted and FEV1 /FVC of 71 ± 8%. They were mildly hypoxemic and the SpO2 was 95 ± 2%.They had a PD15 to mannitol of 235 mg (95% CI: 150-368 mg) and a RDR of 0.057% fall in FEV1 per mg (95% CI: 0.038-0.085). After pre-medication with SCG, PD15 increased (773 mg, P < 0.05) and RDR was reduced (0.013, P < 0.05). Pre-medication with eformoterol also resulted in an increased PD15 (1141 mg, P < 0.01) and a reduced RDR (0.009, P < 0.01). A small but significant decrease in SpO2 from baseline was noted after mannitol in the presence of SCG (P < 0.05).
CONCLUSIONS:
  Pre-medication with either SCG or eformoterol protects patients with bronchiectasis from developing a significant reduction in FEV1 after inhaling mannitol.
AuthorsPeter J Briffa, Sandra D Anderson, Deborah L Burton, Iven H Young
JournalRespirology (Carlton, Vic.) (Respirology) Vol. 16 Issue 1 Pg. 161-6 (Jan 2011) ISSN: 1440-1843 [Electronic] Australia
PMID21054671 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2010 The Authors. Respirology © 2010 Asian Pacific Society of Respirology.
Chemical References
  • Anti-Asthmatic Agents
  • Ethanolamines
  • Mannitol
  • Cromolyn Sodium
  • Oxygen
  • Formoterol Fumarate
Topics
  • Administration, Inhalation
  • Adult
  • Aged
  • Anti-Asthmatic Agents (therapeutic use)
  • Bronchial Provocation Tests
  • Bronchiectasis (drug therapy)
  • Cromolyn Sodium (therapeutic use)
  • Cross-Over Studies
  • Ethanolamines (therapeutic use)
  • Female
  • Forced Expiratory Volume (drug effects)
  • Formoterol Fumarate
  • Humans
  • Male
  • Mannitol (adverse effects, therapeutic use)
  • Middle Aged
  • Oxygen (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: